Stroke: Frequency and prediction factors of haemorrhage in patients with unidentified embolism stroke

For patients with embolis stroke of unknown origin, the risk, location and prediction factors of hemorrhage during anti-embolism treatment are not yet clearIn a recent study published in Stroke, an authoritative journal for cardiovascular disease, researchers conducted an exploratory analysis of haemorrhage as defined by the international standard for thrombosis and hemostatic in 7,213 unidentified cases of embolism in the international NAVIGATE (global trial of the new method of devanssaban inhibitor Xa), a randomized trial comparing the efficacy of 15 mg of levath saban and aspirin of 100 mgDuring the 11-month median follow-up, subjects experienced 85 hemorrhageThe most common site was the gastrointestinal tract (38%), followed by intracranial (29%)Treatment for delavataban (risk ratio of 2.7 (95% CI 1.7-4.3), East Asian countries (HR 2.5 (95% CI 1.6-3.9), sysage pressure of 160mmHg (HR 2.2) The reduction of the rate of renal glomerular filtration (1.2 per 10mL/min/1.73m2, and 1.0-1.3) of 95% CI were independently associated with haemorrhageFive (6%) people diedOf the 15 cases of cerebral hemorrhage, 2 (13%) diedThere is no evidence that Delavsaban enters an early high-risk period after treatmentThe annualized rate of cerebral hemorrhage (0.67%) for participants in East Asian countries was six times higher in all other regions (0.11%; The distribution of the bleeding sites of delavsaban and aspirin is similarIn international randomized trials of patients with unspecified embolism, the independent predictors of haemorrhage were delavsabane, East Asian countries, elevated systolic pressure, and impaired kidney functionEast Asia is closely associated with the risk of cerebral hemorrhageThe estimated rate of glomerular filtration should be considered as a factor to distinguish the risk of bleeding